Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy. Issue 6 (2nd June 2020)

• Record Type: Journal Article
• Authors: Berardicurti, Onorina; Ruscitti, Piero; Pavlych, Viktoriya; Conforti, Alessandro; Giacomelli, Roberto; Cipriani, Paola
• Is Part Of: Expert review of clinical pharmacology. Volume 13:Issue 6(2020)
• Page Start: 593
• Page End: 604
• Publication Date: 2020-06-02
• Subjects: Adverse events -- corticosteroids -- drug efficacy -- glucocorticoids -- rheumatoid arthritis -- therapies; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2020.1772055
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction: Glucocorticoids (GCs) are key actors in RA management, despite the increasing number of available drugs. In fact, due to their efficacy and safety, the combination therapy between GCs and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is still recommended in the early phase of RA treatment, because improving the long-term results. Areas covered: In this paper, we reviewed the role of GCs in RA management, focusing on mechanisms of action as well as the benefit/risk ratio of GCs and newer therapeutic formulations. Furthermore, we analyzed GCs DMARDs proprieties on disease activity and their long-term effects on radiographic damage. We designed a narrative review aimed to provide an overview concerning GCs in RA management. Expert opinion: A large amount of evidence supports the use of GCs in RA, especially in the earliest phases of the disease. Besides GCs symptomatic effects due to their strong anti-inflammatory effects, data from several randomized clinical trials have shown a substantial benefit of low-dose GCs in inhibiting the radiographic damage, thus highlighting GCs DMARDs properties. Besides their recognized role in the treatment of early RA, systematic monitoring of adverse events should be recommended to minimize GCs toxicity.